Page images
PDF
EPUB

Qualified "Educators"?

...he who prescribes for the symptom irrespectively of the cause, is quite as likely to do mischief to his patient as good, and quite as likely to destroy life as to save it." - Jacob Bigelow: Nature in Disease, 1854.

in all diarrheas

CREMOMYCIN

EXPERIENCE

regardless of
etiology

MERCK SHARP & DONISE

Do the advertisements on this page suggest that the "education" of physicians will be materially improved by the copy-writers for the pharmaceutical industry? Would they deny the stern warning of Jacob Bigelow of more than a century ago? Is this aphorism outmoded, or merely set aside for expediency?

In our ignorance we must resort to empirical use of symptomatic therapy to provide relief to patients, but we have been taught to decry this, not to view treatment In modern times,

"regardless of cause" as grounds for complacency or exuberance!

specific treatment for an accurately diagnosed condition is surely a more attainable goal for the scientifically-trained physician, and certainly constitutes the core of teaching in the medical schools.

Does the encouragement of a false sense of security, inherent in claims for effective suppression of symptoms and signs "regardless of cause", lead one to believe that patients will receive a better caliber of medical care from

[merged small][merged small][merged small][merged small][merged small][merged small][ocr errors][merged small][merged small][merged small][merged small][merged small][merged small][ocr errors][ocr errors][ocr errors]
[merged small][merged small][graphic][merged small][ocr errors][subsumed][subsumed][merged small][subsumed][merged small]

Break-through in cystic fibrosis

Pancreatic Insufficiency Deters Fat Absorption

Cystic fibrosis manifests the symptoms of pancreatic insufficiency-diarrhea and steatorrhea with bulky, fetid, frequent stools, loss of weight and appetite. Obstruction of the pancreatic ducts by viscid mucus necessitates administration of complete pancreatic enzyme replacement therapy. The steatorrhea which occurs when total stool fat is more than 10-20% total dietary fat is a predominant symptom in cystic fibrosis because of the absence of lipase activity in the intestine. Stimulation of the gland cannot overcome this pancreatic insufficiency:

[blocks in formation]

Radioactive fat uptake studies by Best, Hightower, et al.,25 document 24 cases of cystic fibrosis of the pancreas. The patients, age 4-18 years, fed [131 Triolein alone, showed a mean peak radioactivity recovery of 2.4% in blood and 64.3% in the stool. When the same amount of I131 Triolein was administered with COTAZYM to the same group of patients, the mean peak recovery in the blood was 7.9% and in the stool 14.4%. The following chart is illustrative:

[blocks in formation]

Thus COTAZYM permits utilization of a well balanced normal diet, aiding control of gastrointestinal manifestations, increasing weight and physical development, and improving emotional development.2.5.6

At last a pancreatic
preparation with
known, constant, measurable
lipase activity

Cotazym

contains a known, constant, large amount of lipase in each capsule. Hence dosage can be geared to the fat content of the diet and based upon the fat-digesting power of the lipase (each capsule digests 17 Gm. dietary fat). COTAZYM also contains adequate amounts of trypsin and amylase to digest accompanying protein and starch.

Each COTAZYM capsule contains:

Lipase 2,000 Organon Units, having a digestive power for 17 Gm. dietary fat.*
Trypsin having a digestive power for 34 Gm. dietary protein.**
Amylase having a digestive power for 40 Gm. dietary starch.**

*Price Method

**N.F. X Method

Break-through in cystic fibrosis

DOSAGE and ADMINISTRATION: COTAZYM is given orally in sufficient quantity to cover every gram of fat in the entire daily diet, including between-meal snacks. Dosage should be calculated to cover adequately the amount of fat in the diet, much in the same manner as the insulin requirement is calculated in diabetes mellitus. Each capsule (2,000 Organon Units of lipase activity) will digest 17 Gm. of fat. With dosage based on the fat-digesting power of the lipase, there is sufficient trypsin and amylase for protein and starch digestion. The capsule may be opened and the contents sprinkled on the food or into milk. COTAZYM capsules should be taken with each meal and each snack, since there is no residual enzyme action from one meal to another. If more than one capsule is required per feeding, the dose should be spread through the meal. When taken with food, the lipase in COTAZYM is protected from gastric destruction and is immediately available for enzymatic function upon duodenal entry.

INDICATIONS: COTAZYM is indicated in conditions where pancreatic enzymes are absent from or present in insufficient amount in the intestine, such as pancreatectomy, chronic pancreatitis with insufficiency, cystic fibrosis of the pancreas, steatorrhea, and in other malabsorptive states in which fat digestion is inadequate due to deficiency of pancreatic enzymes. There are no contraindications.

SUPPLIED: Bottles of 100 green capsules.

REFERENCES: 1. Maddock, C., Farber, S., Schwachman, H.: Am. J. Dis.
Child., 66:370, 1943. 2. Best, E. B., Hightower, N. C., Williams, B. H. and
Carabasi, R. J., "Pancreatic Replacement Therapy in Fibrocystic Disease,"
read before the Section on Gastroenterology, Southern Medical Association,
Atlanta, Ga., Nov. 16-19, 1959. 3. Nelson, W., Textbook of Pediatrics, 7th
Ed., W. B. Saunders & Co., Phila., 1959, p. 729. 4. Slobody, L. B., Survey
Clinical Pediatrics, 3rd Ed., McGraw-Hill Co., New York, 1959, pp. 305-309.
5. Best, E. B., Hightower, N. C., Williams, B. H. and Carabasi, R. J., "Cystic
Fibrosis of the Pancreas: Pancreatic Replacement Therapy," Symposium on
Pancreatic Insufficiency and Fibrocystic Disease, Organon Inc., West Orange,
N. J., May 11, 1960. 6. Steigmann, F., "Malabsorption," Symposium on Mal-
absorption, N. J. Gastroenterology Soc., Newark, N. J., March 29, 1960.

Cotazym

known, constant, measurable lipase activity

[graphic]

COT-DP-SU

Organon ORGANON INC., West Orange, New Jersey

PTD. IN S.A

« PreviousContinue »